Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class:
Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [10]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,5,9].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use ![]() |
The US FDA issued accelerated approval for mirvetuximab soravtansine in November 2022 [6]. This authorisation indicated mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer [4,9]. Drug-induced ocular (corneal) toxicity has been noted, but can be resolved with short-term topical steroid administration [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | Phase 3 Interventional | ImmunoGen, Inc. | 9 | |
NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | Phase 1/Phase 2 Interventional | ImmunoGen, Inc. | 8 | |
NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | Phase 3 Interventional | ImmunoGen, Inc. | 7 |